10x Genomics $TXG Shares Acquired by Sei Investments Co.

Sei Investments Co. increased its holdings in shares of 10x Genomics (NASDAQ:TXG) by 113.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,679 shares of the company’s stock after purchasing an additional 23,748 shares during the period. Sei Investments Co.’s holdings in 10x Genomics were worth $949,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. First Trust Advisors LP purchased a new stake in shares of 10x Genomics during the 1st quarter valued at about $271,000. Quantedge Capital Pte Ltd lifted its position in 10x Genomics by 104.2% during the 1st quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock worth $8,843,000 after acquiring an additional 212,600 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in 10x Genomics by 34.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock worth $43,357,000 after acquiring an additional 525,369 shares during the period. Swiss National Bank boosted its holdings in 10x Genomics by 2.2% in the 1st quarter. Swiss National Bank now owns 207,400 shares of the company’s stock worth $4,403,000 after acquiring an additional 4,400 shares during the period. Finally, Kera Capital Partners Inc. boosted its holdings in 10x Genomics by 2.3% in the 1st quarter. Kera Capital Partners Inc. now owns 48,937 shares of the company’s stock worth $1,039,000 after acquiring an additional 1,108 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at 10x Genomics

In other news, insider Benjamin J. Hindson sold 11,595 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $283,381.80. Following the transaction, the insider owned 502,000 shares of the company’s stock, valued at approximately $12,268,880. This trade represents a 2.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Taich sold 15,098 shares of the business’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $24.44, for a total value of $368,995.12. Following the completion of the sale, the chief financial officer directly owned 379,898 shares of the company’s stock, valued at approximately $9,284,707.12. This represents a 3.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 91,309 shares of company stock worth $2,581,357 over the last quarter. Company insiders own 8.84% of the company’s stock.

10x Genomics Trading Down 1.2%

TXG stock opened at $57.75 on Thursday. 10x Genomics has a twelve month low of $11.16 and a twelve month high of $60.69. The company has a market capitalization of $7.33 billion, a P/E ratio of -97.88 and a beta of 2.03. The firm has a 50 day simple moving average of $40.93 and a 200-day simple moving average of $28.43.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.10. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.41%. The business had revenue of $151.04 million during the quarter, compared to analyst estimates of $146.67 million. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The business’s revenue was down 12.7% compared to the same quarter last year. On average, research analysts predict that 10x Genomics will post -0.79 EPS for the current year.

Analyst Ratings Changes

TXG has been the topic of a number of analyst reports. Bank of America lifted their price objective on shares of 10x Genomics from $21.00 to $30.00 and gave the company a “neutral” rating in a research note on Monday, April 20th. Canaccord Genuity Group raised their price target on shares of 10x Genomics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Monday. Piper Sandler lifted their price target on shares of 10x Genomics from $42.00 to $47.00 and gave the stock a “neutral” rating in a research note on Monday. JPMorgan Chase & Co. boosted their price objective on shares of 10x Genomics from $17.00 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. Finally, Barclays upped their price objective on shares of 10x Genomics from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, 10x Genomics has an average rating of “Hold” and an average price target of $38.31.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.